# SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

> **NCT05039944** · PHASE2 · TERMINATED · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** SI-B001
- **DRUG:** Irinotecan
- **DRUG:** FOLFIRI Protocol
- **DRUG:** FOLFOX Protocol

## Key facts

- **NCT ID:** NCT05039944
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-30
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-06-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Company research strategy adjustment
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039944, "SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05039944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*